2. Academic Validation
  3. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

  • J Med Chem. 2013 Jul 25;56(14):5979-83. doi: 10.1021/jm400487c.
Qingjie Ding 1,  Zhuming Zhang,  Jin-Jun Liu,  Nan Jiang,  Jing Zhang,  Tina M Ross,  Xin-Jie Chu,  David Bartkovitz,  Frank Podlaski,  Cheryl Janson,  Christian Tovar,  Zoran M Filipovic,  Brian Higgins,  Kelli Glenn,  Kathryn Packman,  Lyubomir T Vassilev,  Bradford Graves
Affiliations

Affiliation

  • 1 Discovery Chemistry, ‡Discovery Technologies, §Discovery Oncology, ∥Non-Clinical Development, Roche Research Center, Hoffmann-La Roche, Inc. , 340 Kingsland Street, Nutley, New Jersey 07110, United States.
PMID: 23808545 DOI: 10.1021/jm400487c
Abstract

Restoration of p53 activity by inhibition of the p53-MDM2 interaction has been considered an attractive approach for Cancer treatment. However, the hydrophobic protein-protein interaction surface represents a significant challenge for the development of small-molecule inhibitors with desirable pharmacological profiles. RG7112 was the first small-molecule p53-MDM2 inhibitor in clinical development. Here, we report the discovery and characterization of a second generation clinical MDM2 Inhibitor, RG7388, with superior potency and selectivity.

Figures
Products